Novo A/S to expand its investment activities  

2008.12.23
Novo A/S, the holding company of the Novo Group, has announced plans to increase its focus on building successful life science companies
Novo A/S, the holding company of the Novo Group, has announced in a press release that its plans to increase its focus on building successful life science companies. Previously, Novo has put venture capital into promising early-stage life science companies. The new initiative will be to invest 'growth equity' in promising later-stage/commercial-stage life science companies.
 
The financial capacity of Novo has strengthened in recent years due to the successful performance of its underlying portfolio, in particular world-leading insulin manufacturer Novo Nordisk and industrial enzyme giant Novozymes.
 
Novo writes that it is launching its initiative now "in response to the overwhelming need for development capital in smaller life science companies internationally". With an illustrious heritage in the pharma industry and a decade of involvement in life science venture capital, Novo is seeking to become an active investor in this new area.
 
Link > Novo                          

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×